Genedrive PLC Publication of Circular and Notice of GM (2438X)

TIDMGDR

RNS Number : 2438X

Genedrive PLC

24 April 2023

genedrive plc

("genedrive", the "Group" or the "Company")

Publication of Circular and Notice of General Meeting

London, UK - 24 April 2023: genedrive plc (LSE: GDR), the point of care molecular diagnostics company, announces that further to the announcement on 31 March 2023 confirming that it had agreed terms on an Equity Prepayment Facility for up to GBP5 million, a Circular will shortly be published on the Company's website, www.genedriveplc.com, and will be posted to Shareholders later today.

The Circular contains the notice convening the General Meeting to be held at 11.00 a.m. on 11 May 2023 at which resolutions will be proposed to authorise the allotment of new ordinary shares and the disapplication of pre-emption rights.

For further information, please contact:

 
 genedrive plc                                                     [phone] 
 David Budd (Chief Executive Officer) 
  Russ Shaw (Chief Financial Officer) 
 
 Peel Hunt LLP - Nominated Adviser, Joint 
  Broker                                                           [phone] 
 James Steel / Oliver Duckworth 
 
 finnCap Ltd - Joint Broker                                        [phone] 
 Geoff Nash / George Dollemore 
 
 Walbrook PR - Financial PR & IR 
  Adviser                                                          [phone] 
 Paul McManus / Anna Dunphy                                 Or [e-mail] 
 
 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

The Genedrive(R) MT-RNR1 ID Kit, selected as 1 of the 10 EVA pilot projects, is the world's first commercial point-of-care genetic test for emergency care. It helps to avoid irreversible lifelong hearing loss in specific infants exposed to aminoglycosides by rapidly detecting the m.1555A>G gene variant that can cause lifelong deafness, allowing for alternative antibiotics to be prescribed. Product information can be found at https://www.genedrive.com/assays/rnr1-product.php

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGSEEFSLEDSEIL

(END) Dow Jones Newswires

April 24, 2023 06:54 ET (10:54 GMT)